Aparna Pharmaceuticals, a key player in manufacturing Active Pharmaceutical Ingredients (APIs) and Advanced Drug Intermediates, on Monday announced that its manufacturing facility, Aparna Organics Limited, located in Pydibhimavaram, Srikakulalam, Andhra Pradesh, India has received VAI classification from the United States Food and Drug Administration (USFDA). The USFDA audited the facility during the month of September 2023.
This achievement underscores Aparna’s unwavering commitment to quality and compliance with global regulatory requirements, it claimed.
“This clearance is a testament to our team’s relentless pursuit of excellence. Our facility’s compliance journey has been meticulous. We are thrilled to receive the USFDA’s stamp of approval. We are excited to contribute to global healthcare by delivering high quality pharmaceutical APIs and intermediates,” Rakesh Reddy, Managing Director, Aparna Pharmaceuticals said in a statement.
With the successful completion of the FDA audit, Aparna Pharmaceuticals has emerged as a leading manufacturer of APIs and Advanced Drug Intermediates and attained global recognition by providing high quality products manufactured as per cGMP guidelines, the company stated.
Driven by innovative R&D and optimum utilization of resources, the company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies, it added.
